Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329325 | 0.93 | SLC9A1 (0.36) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4322273 | 0.86 | MAPT (0.38) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4331899 | 0.86 | LMNA (0.37) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4338702 | 0.83 | NPFFR1 (0.50) | MAPTMEN1KMT2AATMSLC9A1 | |
| SCHEMBL4338712 | 0.82 | MAPT (0.51) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4330988 | 0.82 | NPFFR1 (0.53) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4324316 | 0.79 | MAPT (0.38) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4451555 | 0.78 | KDM4E (0.50) | MAPTMEN1KMT2ASLC9A1ALDH1A1 | |
| SCHEMBL4464598 | 0.76 | HKDC1 (0.54) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4464609 | 0.76 | HKDC1 (0.54) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | TP53 838/4885MAPT 3876/4885MEN1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.